Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Change in Accured Expenses (2019 - 2025)

Historic Change in Accured Expenses for Madrigal Pharmaceuticals (MDGL) over the last 13 years, with Q3 2025 value amounting to $187.5 million.

  • Madrigal Pharmaceuticals' Change in Accured Expenses rose 111840.57% to $187.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $214.0 million, marking a year-over-year increase of 34223.96%. This contributed to the annual value of $34.7 million for FY2024, which is 244402.43% up from last year.
  • Madrigal Pharmaceuticals' Change in Accured Expenses amounted to $187.5 million in Q3 2025, which was up 111840.57% from $33.3 million recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' Change in Accured Expenses registered a high of $187.5 million during Q3 2025, and its lowest value of -$6.3 million during Q4 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $3.3 million (2021), whereas its average is $15.8 million.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 28148.73% in 2021, then soared by 171295.64% in 2024.
  • Madrigal Pharmaceuticals' Change in Accured Expenses (Quarter) stood at -$3.5 million in 2021, then skyrocketed by 443.56% to $11.9 million in 2022, then plummeted by 37.87% to $7.4 million in 2023, then crashed by 185.59% to -$6.3 million in 2024, then skyrocketed by 3073.0% to $187.5 million in 2025.
  • Its Change in Accured Expenses stands at $187.5 million for Q3 2025, versus $33.3 million for Q2 2025 and -$530000.0 for Q1 2025.